Objective

2

To investigate the synergistic effect of Xiangdan injection （XDI） and Qingkailing injection （QKLI） in the treatment of inflammation and thrombosis animal model based on changes of thrombus， inflammatory indexes， organ function， and pathological changes.

Method

2

A total of 100 male SD rats were randomly divided into a normal control group， a model group， XDI groups （2.5， 5 mL·kg

-1

）， QKLI groups （5， 10 mL·kg

-1

）， and XDI + QKLI groups ［（2.5+5） mL·kg

-1

，（2.5+10） mL·kg

-1

，（5+5） mL·kg

-1

，and （5+10） mL·kg

-1

］ according to the body weight， with 10 rats in each group. Rats were treated correspondingly by intraperitoneal injection once a day for 4 days. The normal control group and the model group received normal saline. On the second day of administration， the model was induced in rats except those in the normal control group. Specifically， 25 mg·kg

-1

carrageenan was injected intraperitoneally into the rats， followed by an injection of 50 μg·kg

-1

lipopolysaccharide （LPS） through the tail vein 16 hours later. Twenty-four hours after LPS injection， the rats were detected for liver index， kidney index， the number of platelets （PLT）， thrombus length， and biochemical indicators such as aspartate aminotransferase （AST）， alanine aminotransferase （ALT）， alkaline phosphatase （ALP）， creatinine， and blood urea nitrogen （BUN）. Enzyme-linked immunosorbent assay （ELISA） was used to determine the content of inflammatory factors interleukin-6 （IL-6） and tumor necrosis factor-

α

（TNF-

α

）. Hematoxylin-eosin （HE） staining was used to observe the histopathological changes of heart， liver， lung， and kidney， as well as the grading of organ injury.

Result

2

Compared with the normal group， the model group showed decreased PLT， lengthened thrombus in the tail， increased liver index， elevated content of ALT， ALP， BUN， IL-6， and TNF-

α

（

P

<

0.05，

P

<

0.01）， and damaged liver， lung， and kidney tissues （

P

<

0.05，

P

<

0.01）. Compared with the conditions in the model group， XDI at 5 mL·kg

-1

reduced serum ALT and ALP in rats （

P

<

0.05，

P

<

0.01）， QKLI at 5 and 10 mL·kg

-1

reduced serum levels ALT and ALP， and TNF-

α

content

（

P

<

0.05，

P

<

0.01）. XDI at 5 mL·kg

-1

or QKLI at 10 mL·kg

-1

relieved the LPS-induced lung injury （

P

<

0.05）， the combination of XDI and QKLI decreased the levels of ALT， AST， ALP， and TNF-

α，

and the effect was predominant in the combination of XDI and QKLI at 5 and 10 mL·kg

-1

（

P

<

0.05，

P

<

0.01）. Additionally， the length of the tail thrombus was significantly shortened （

P

<

0.05）， and the degree of lung injury was also reduced （

P

<

0.05）. The serum levels of ALT and BUN， TNF-

α

content， and liver index of rats were reduced after the combination of XDI and QKLI as compared with those in the single drug groups at the same dose （

P

<

0.05，

P

<

0.01）.

Conclusion

2

XDI or QKLI can improve or inhibit organ function， organ injury， and inflammatory response in the rat model of inflammation and thrombosis. The combination of the two drugs shows a synergistic effect in reducing the length of venous thrombus， improving liver and kidney function， inhibiting inflammatory factors， and protecting lung， liver， kidney， and other organs.